DCSZ11 + doxorubicin

DCSZ11 + doxorubicin is a combination investigational therapy for advanced or metastatic solid tumors. **DCSZ11** is a monoclonal antibody targeting CD93, a protein involved in vascular biology and tumor angiogenesis. **Doxorubicin** is a widely used small molecule anthracycline chemotherapeutic that inhibits topoisomerase II, intercalates DNA, and induces reactive oxygen species, leading to apoptosis and cell death. This combination aims to synergize anti-angiogenic (by blocking CD93) and cytotoxic (by doxorubicin) mechanisms to suppress tumor growth, improve response rates, and reduce resistance, especially in solid tumors such as breast cancer. The primary indication under investigation is advanced/metastatic solid tumors, and the combination is being evaluated in phase 1 trials for efficacy and safety[1][5].